Overview

Stereotactic Radiotherapy Combined With Adebrelimab and TCb (Nab-paclitaxel + Carboplatin) in Neoadjuvant Treatment of TNBC

Status:
Recruiting

Trial end date:
2028-12-15

Target enrollment:

Participant gender:

Summary

This study was an open-label, multicenter, randomized study. It is planned to include 136 patients with stage II-III triple negative breast cancer. Eligible subjects will be randomized to receive either the experimental arm: adebrelimab plus stereotactic radiotherapy followed by adebrelimab plus chemotherapy (nab-paclitaxel + carboplatin) or the control arm: adebrelimab plus nab-paclitaxel + carboplatin.

Phase:

Phase 2

Details

Lead Sponsor:

Shengjing Hospital

Treatments:

Albumin-Bound Paclitaxel
Carboplatin
Paclitaxel